Xencor licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development for the optimization of Centocor’s antibody drug candidates. Under the multiyear agreement, Centocor will gain access to both the XmAb and Xtend technology platforms and has the right to develop and commercialize a specified number of optimized candidates. Xencor will receive license fees and is eligible to receive milestones and royalties on products commercialized from the collaboration.
Xtend antibody technology platform helps enhance the serum half-life of immunoglobulin molecules. The XmAb platform can increase the potency of therapeutic antibodies by specifically engaging the body’s immune system against target antigen cells, according to Xencor.
